May 15, 2019
Powles T et al. Nature Medicine 2019;25:1706–1714.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
You might also be interested by
Scientific Publications
Microenvironmental regulation of tumour immunity and response to immunotherapy
April 13, 2021
Histopathology
More infoPress Releases
Caprion-HistoGeneX expands its histological biomarker franchise by joining forces with Mosaic Laboratories
January 12, 2021
Histopathology
More info